Table 1.
Clinicopathological variables and the expression of DBC1 and BRCA1 in ovarian carcinomas
| Characteristics | No. | Overall ovarian car | cinomas | No. | Serous c | Arcinomas | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DBC1+ | P | BRCA1+ | P | DBC1+ | P | BRCA1+ | P | ||||
| Age, y | <60 | 71 | 41 (58%) | 0.076 | 28 (39%) | 0.149 | 45 | 29 (64%) | 0.074 | 20 (44%) | 0.450 |
| ≥60 | 33 | 25 (76%) | 18 (55%) | 30 | 25 (83%) | 16 (53%) | |||||
| Stage | I & II | 52 | 27 (52%) | 0.015 | 21 (40%) | 0.430 | 29 | 18 (62%) | 0.128 | 13 (45%) | 0.662 |
| III & IV | 52 | 39 (75%) | 25 (48%) | 46 | 36 (78%) | 23 (50%) | |||||
| Tumor size, cm | ≤10 | 68 | 48 (71%) | 0.038 | 31 (46%) | 0.702 | 56 | 40 (71%) | 0.850 | 26 (46%) | 0.64 |
| >10 | 36 | 18 (50%) | 15 (42%) | 19 | 14 (74%) | 10 (53%) | |||||
| LN metastasis | Absence | 84 | 50 (60%) | 0.087 | 37 (44%) | 0.939 | 56 | 39 (70%) | 0.435 | 28 (50%) | 0.552 |
| Presence | 20 | 16 (80%) | 9 (45%) | 19 | 15 (79%) | 8 (42%) | |||||
| Ascites | Absence | 71 | 41 (58%) | 0.076 | 28 (39%) | 0.149 | 45 | 31 (69%) | 0.462 | 18 (40%) | 0.089 |
| Presence | 33 | 25 (76%) | 18 (55%) | 30 | 23 (77%) | 18 (60%) | |||||
| Bilaterality | Unilateral | 59 | 31 (53%) | 0.008 | 24 (41%) | 0.404 | 34 | 21 (62%) | 0.072 | 16 (47%) | 0.882 |
| Bilateral | 45 | 35 (78%) | 22 (49%) | 41 | 33 (80%) | 20 (49%) | |||||
| LD Meta | Absence | 76 | 43 (57%) | 0.016 | 28 (37%) | 0.012 | 52 | 34 (65%) | 0.055 | 21 (40%) | 0.047 |
| Presence | 28 | 23 (82%) | 18 (64%) | 23 | 20 (87%) | 15 (65%) | |||||
| Platinum-resistance | Absence | 62 | 38 (61%) | 0.016 | 21 (34%) | 0.014 | 48 | 32 (67%) | 0.008 | 19 (40%) | 0.043 |
| Presence | 20 | 18 (90%) | 13 (65%) | 16 | 16 (100%) | 11 (69%) | |||||
| CA19-9 | Normal | 66 | 47 (71%) | 0.060 | 32 (48%) | 0.158 | 50 | 39 (78%) | 0.341 | 26 (52%) | 0.156 |
| Elevated | 17 | 8 (47%) | 5 (29%) | 8 | 5 (63%) | 2 925%) | |||||
| CA125 | Normal | 18 | 7 (39%) | 0.004 | 5 (28%) | 0.121 | 7 | 4 (57%) | 0.249 | 4 (57%) | 0.630 |
| Elevated | 75 | 56 (75%) | 36 (48%) | 61 | 47 (77%) | 29 (48%) | |||||
| Histologic grade | Low (1) | 27 | 5 (19%) | <0.001 | 6 (22%) | 0.007 | 12 | 4 (33%) | 0.001 | 4 (33%) | 0.267 |
| High (2 & 3) | 77 | 61 (79%) | 40 (52%) | 63 | 50 (79%) | 32 (51%) | |||||
| Histologic type | Serous | 75 | 54 (72%) | <0.001 | 36 (48%) | 0.254 | |||||
| Mucinous | 20 | 3 (15%) | 5 (25%) | ||||||||
| Endometrioid | 5 | 5 (100%) | 3 (60%) | ||||||||
| Clear cell | 3 | 3 (100%) | 1 (33%) | ||||||||
| Malignant Brenner | 1 | 1 (100%) | 1 (100%) | ||||||||
| BRCA1 | Negative | 58 | 28 (48%) | <0.001 | 39 | 22 (56%) | 0.002 | ||||
| Positive | 46 | 38 (83%) | 36 | 32 (89%) | |||||||
LN; lymph node, LD Meta; latent distant metastasis.